Discover the latest breakthroughs in multiple myeloma treatment, including CAR T-cell therapies and promising new options for ...

Panelists discuss how treatment decisions in multiple myeloma are guided by disease risk, patient health, and evolving clinical data—highlighting the shift toward a comprehensive, multi-phase approach ...

Stage 1 multiple myeloma features low beta-2 microglobulin, high albumin, and no organ damage, often detected incidentally. Diagnosis involves blood, urine, imaging tests, and bone marrow biopsy to ...

To be accepted into a clinical trial, all potential participants must meet the "eligibility criteria" by having similar ...

Researchers have reported promising results from a new treatment approach that appears to reverse an aggressive form of blood ...

The National Comprehensive Cancer Network provides a list of preferred primary therapy regimens for transplant-eligible and nontransplant candidates and lists drugs recommended for maintenance therapy ...

Experts discuss the evolving role of bispecific antibodies in multiple myeloma, highlighting treatment advancements and ...

Experts discuss the critical challenges in accessing innovative treatments for relapsed refractory multiple myeloma, ...

The latest data released at ASH 2025 offer new combination therapies for the treatment of multiple myeloma and new insights into the disease.

Treatment for multiple myeloma has evolved significantly, with long-term survival increasingly within reach for many patients. Achieving optimal outcomes requires not only addressing symptoms but also ...

Radiation therapy is a treatment that uses high doses of radiation to damage cancer cells, either killing them or slowing their growth. Unlike the low-dose radiation used in X-rays to see inside the ...

Editor's note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. So I think, as I mentioned earlier, we've ...